Biotie Therapies - Company Announcement

Biotie regains rights to develop PDE10 inhibitors for CNS disorders

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 15 October 2010 at 12.15

Biotie regains rights to develop PDE10 inhibitors for CNS disorders

Biotie announced today that it will regain rights to compounds relating to PDE10
inhibition for the treatment of CNS disorders, including schizophrenia. The
compounds were the subject of a four-year collaboration with Wyeth (which was
acquired by Pfizer in 2009) which started in 2006 and which yielded several
promising PDE10 inhibitors that have demonstrated activity in pre-clinical
models of schizophrenia.

Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about
PDE10 as a novel target for the treatment of schizophrenia and other disorders
of the central nervous system. We have had a succesful research collaboration
with Wyeth, and then Pfizer, and together we have generated supportive data for
this class. We are now in a position to pursue novel clinical candidates going
forward."

Turku, 15 October 2010

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager

tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com

Distribution:

NASDAQ OMX Helsinki Ltd
Main Media

ABOUT BIOTIE THERAPIES

Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and pre-
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.

Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com



[HUG#1452271]